-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

Benzinga·10/15/2026 21:31:15
Listen to the news
UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.